U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06898359) titled 'Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer' on March 21.
Brief Summary: This research investigates the role of the gut microbe in patients receiving radioimmunotherapy with locally advanced microsatellite-stable (MSS) rectal cancer. Given the limitations of current treatment strategies in achieving optimal clinical outcomes, this prospective, single-center, phase II clinical trial aims to improve pathological complete response (pCR) rates. The primary endpoint is pCR, with secondary endpoints including disease-free survival (DFS) and the incidence of treatment-related adverse ev...